FMR CORP 13D and 13G filings for Kymera Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 10:32 am Purchase |
2024-11-08 | 13G | Kymera Therapeutics, Inc. KYMR |
FMR CORP | 5,109,141 7.933% |
2,761,614 (+117.64%) |
Filing |
| 2022-02-09 09:22 am Sale |
2022-02-08 | 13G | Kymera Therapeutics, Inc. KYMR |
FMR CORP | 2,347,527 4.568% |
-94,533 (-3.87%) |
Filing |
| 2021-02-08 10:27 am Purchase |
2021-02-05 | 13G | Kymera Therapeutics, Inc. KYMR |
FMR CORP | 2,442,060 5.492% |
2,442,060 (New Position) |
Filing |